OA12080A - Sodium-hydrogen exchanger type 1 inhibitor crystals. - Google Patents

Sodium-hydrogen exchanger type 1 inhibitor crystals. Download PDF

Info

Publication number
OA12080A
OA12080A OA1200200128A OA1200200128A OA12080A OA 12080 A OA12080 A OA 12080A OA 1200200128 A OA1200200128 A OA 1200200128A OA 1200200128 A OA1200200128 A OA 1200200128A OA 12080 A OA12080 A OA 12080A
Authority
OA
OAPI
Prior art keywords
recited
daim
tissue
rel
crystal
Prior art date
Application number
OA1200200128A
Other languages
English (en)
Inventor
Lyle Robinson Brostrom
Terrence Joseph Connolly
Jane Li Zheng
Susan Lee Orrill
Bharat Kiritkumar Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA12080A publication Critical patent/OA12080A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
OA1200200128A 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals. OA12080A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29

Publications (1)

Publication Number Publication Date
OA12080A true OA12080A (en) 2003-08-25

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200128A OA12080A (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals.

Country Status (44)

Country Link
EP (1) EP1224179B1 (zh)
JP (1) JP2003512455A (zh)
KR (1) KR100464526B1 (zh)
CN (2) CN1636991A (zh)
AP (1) AP2002002493A0 (zh)
AR (1) AR029402A1 (zh)
AT (1) ATE271047T1 (zh)
AU (1) AU778573B2 (zh)
BG (1) BG106729A (zh)
BR (1) BR0015275A (zh)
CA (1) CA2389020A1 (zh)
CO (1) CO5271714A1 (zh)
CZ (1) CZ20021332A3 (zh)
DE (1) DE60012208T2 (zh)
DK (1) DK1224179T3 (zh)
DZ (1) DZ3463A1 (zh)
EA (1) EA004937B1 (zh)
EE (1) EE200200227A (zh)
ES (1) ES2222923T3 (zh)
GE (1) GEP20043222B (zh)
GT (1) GT200000180A (zh)
HK (1) HK1048472B (zh)
HR (1) HRP20020366B1 (zh)
HU (1) HUP0204009A3 (zh)
IL (1) IL148581A0 (zh)
IS (1) IS6302A (zh)
MA (1) MA26840A1 (zh)
MX (1) MXPA02004358A (zh)
NO (1) NO20021821L (zh)
NZ (1) NZ517738A (zh)
OA (1) OA12080A (zh)
PA (1) PA8505501A1 (zh)
PE (1) PE20010764A1 (zh)
PL (1) PL354869A1 (zh)
PT (1) PT1224179E (zh)
SI (1) SI1224179T1 (zh)
SK (1) SK5312002A3 (zh)
SV (1) SV2002000209A (zh)
TN (1) TNSN00210A1 (zh)
TR (1) TR200201167T2 (zh)
UA (1) UA72002C2 (zh)
WO (1) WO2001030759A2 (zh)
YU (1) YU31502A (zh)
ZA (1) ZA200203295B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
CA2436539A1 (en) * 2001-01-31 2002-08-08 Pfizer Products Inc. Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
MXPA04006615A (es) * 2002-01-30 2004-10-04 Pfizer Prod Inc Composiciones farmaceuticas de mesilato de zoniporida y procedimientos para mejorar la solubilidad de la zoniporida.
EP1499317A1 (en) * 2002-05-02 2005-01-26 Pfizer Products Inc. Treatment of diabetes and diabetic complications with nhe-1 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1454902A1 (en) * 1998-02-27 2004-09-08 Pfizer Products Inc. N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia

Also Published As

Publication number Publication date
CZ20021332A3 (cs) 2002-10-16
DK1224179T3 (da) 2004-10-25
MA26840A1 (fr) 2004-12-20
DE60012208D1 (de) 2004-08-19
WO2001030759A3 (en) 2001-09-13
PT1224179E (pt) 2004-10-29
TNSN00210A1 (fr) 2005-11-10
ATE271047T1 (de) 2004-07-15
IL148581A0 (en) 2002-09-12
MXPA02004358A (es) 2002-11-07
HUP0204009A3 (en) 2004-07-28
GT200000180A (es) 2002-04-11
NZ517738A (en) 2005-06-24
NO20021821D0 (no) 2002-04-18
HRP20020366A2 (en) 2004-02-29
CN1384829A (zh) 2002-12-11
TR200201167T2 (tr) 2002-08-21
DE60012208T2 (de) 2005-07-21
ZA200203295B (en) 2003-06-25
KR100464526B1 (ko) 2005-01-03
HK1048472B (zh) 2005-09-16
BG106729A (bg) 2002-12-29
SK5312002A3 (en) 2003-01-09
AR029402A1 (es) 2003-06-25
BR0015275A (pt) 2002-07-16
AP2002002493A0 (en) 2002-06-30
YU31502A (sh) 2004-12-31
GEP20043222B (en) 2004-04-26
PA8505501A1 (es) 2003-09-05
EA004937B1 (ru) 2004-10-28
CO5271714A1 (es) 2003-04-30
EP1224179A2 (en) 2002-07-24
NO20021821L (no) 2002-04-18
CA2389020A1 (en) 2001-05-03
JP2003512455A (ja) 2003-04-02
EP1224179B1 (en) 2004-07-14
WO2001030759A2 (en) 2001-05-03
EA200200416A1 (ru) 2002-10-31
PL354869A1 (en) 2004-03-08
SV2002000209A (es) 2002-07-16
AU7441500A (en) 2001-05-08
PE20010764A1 (es) 2001-07-23
AU778573B2 (en) 2004-12-09
HK1048472A1 (en) 2003-04-04
UA72002C2 (en) 2005-01-17
DZ3463A1 (fr) 2001-05-03
HRP20020366B1 (en) 2005-04-30
CN1205205C (zh) 2005-06-08
HUP0204009A2 (hu) 2003-03-28
KR20020040918A (ko) 2002-05-30
ES2222923T3 (es) 2005-02-16
IS6302A (is) 2002-03-15
CN1636991A (zh) 2005-07-13
EE200200227A (et) 2003-06-16
SI1224179T1 (en) 2004-10-31

Similar Documents

Publication Publication Date Title
EA021025B1 (ru) Соединения, эффективные в качестве ингибиторов ксантиноксидазы, способ их получения и содержащая их фармацевтическая композиция
JP4075064B2 (ja) ４，４−ジフルオロ−１，２，３，４−テトラヒドロ−５ｈ−１−ベンゾアゼピン誘導体又はその塩
LV11614B (en) Substituted n-(indole-2-carbonyl)-©-alaninamides and derivatives as antidiabetic agents
OA12080A (en) Sodium-hydrogen exchanger type 1 inhibitor crystals.
OA12256A (en) Sodium-hydrogen exchanger type 1 inhibitor (NHE-1).
TWI221152B (en) Method for preparing sodium-hydrogen exchanger type 1 inhibitor
US20010051634A1 (en) Sodium-hydrogen exchanger type 1 inhibitor
AU2005201428A1 (en) Method for preparing sodium-hydrogen exchanger type 1 inhibitor
JPS62289560A (ja) 新規ホモベラトリルアミン誘導体及びその製造法